Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells

T-cell lymphomas are aggressive lymphomas that often resist current therapy options or present with relapsed disease, making the development of more effective treatment regimens clinically important. Previously, we have shown that CD4 CAR can effectively target T-cell malignancies in preclinical stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jia, Xu, Haichan, Cinquina, Andrew, Wu, Zehua, Zhang, Wenli, Sun, Lihua, Chen, Qi, Tian, Lei, Song, Le, Pinz, Kevin G., Wada, Masayuki, Jiang, Xun, Hanes, William M., Ma, Yupo, Zhang, Hongyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511023/
https://www.ncbi.nlm.nih.gov/pubmed/36172388
http://dx.doi.org/10.3389/fimmu.2022.997482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511023/
https://www.ncbi.nlm.nih.gov/pubmed/36172388
http://dx.doi.org/10.3389/fimmu.2022.997482

Ejemplares similares